Last updated July 4, 2026
Key finding
Mean changes in HbA1c from baseline to week 20 ranged from -1.41% to -1.67% with mazdutide.
This Phase 2 trial evaluated the efficacy and safety of Mazdutide in Chinese patients with Type 2 Diabetes, showing significant improvements in glycemic control and weight loss.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This Phase 2 trial evaluated the efficacy and safety of Mazdutide in Chinese patients with Type 2 Diabetes, showing significant improvements in glycemic control and weight loss.
The findings suggest that Mazdutide could be an effective treatment for Type 2 Diabetes, offering patients improved glycemic control and weight management. This is particularly important as effective diabetes management can reduce the risk of complications associated with the disease.
Limited generalizability due to the study being conducted only in Chinese patients. Potential biases inherent in a double-blind trial design. Short duration of 20 weeks may not capture long-term effects.
Published in
Publication details and source links for this paper.
Bo Z, Zhifeng C, Ji C, et al. Efficacy and Safety of Mazdutide in Chinese Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Diabetes Care. 2024;47(1):160-168. doi:10.2337/dc23-1287
Mazdutide reduced HbA1c by -1.5% (p=0.0001) from baseline to week 20.
Participants experienced a mean body weight reduction of -7.1% with Mazdutide.
A higher proportion of participants achieved HbA1c < 7.0% with Mazdutide compared to placebo.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Mazdutide 3 mg and AST, Adverse events incidence, Alanine Aminotransferase (ALT), and 12 more.
This study contributes evidence to
Primary intervention
Mazdutide 3 mg
Primary outcomes
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
4
Related topics
15
Evidence pairs
791
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence relationship
Save evidence
Evidence relationship
Save evidence
Core evidence
The primary outcomes reported in this study.
Mazdutide 3 mg → Adverse events incidence
Mazdutide 3 mg → Adverse events incidence
Mazdutide 3 mg → Alanine Aminotransferase (ALT)
Mazdutide 3 mg → Alanine Aminotransferase (ALT)
Mazdutide 3 mg → Diastolic blood pressure
Mazdutide 3 mg → Diastolic blood pressure
Mazdutide 3 mg → Fasting Plasma Glucose (FPG)
Mazdutide 3 mg → Fasting Plasma Glucose (FPG)
Mazdutide 3 mg → Proportion achieving HbA1c <7.0%
Mazdutide 3 mg → Proportion achieving HbA1c <7.0%
Mazdutide 3 mg → Systolic blood pressure
Mazdutide 3 mg → Systolic blood pressure
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Adverse events incidence, GLP-1 Receptor Agonists and Adipokine and Angiogenic Markers.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Adipokine and Angiogenic Markers
Measures Adipokine and Angiogenic Markers as a key outcome.
All studies measuring Adverse events incidence
Measures Adverse events incidence as a key outcome.
All studies measuring Body Weight
Measures Body Weight as a key outcome.
All studies on GLP-1 Receptor Agonists
Contributes to GLP-1 Receptor Agonists evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Proportion achieving HbA1c <7.0%
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 29 supporting studies with consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists appears to improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Body weight
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 30 supporting studies with consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists may improve Body Mass Index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
BMI
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 15 supporting studies with consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists may improve Fasting Glucose.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Blood glucose
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Fasting Plasma Glucose (FPG)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 11 supporting studies with generally consistent results and a positive effect signal.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
